INTRODUCTION AND OBJECTIVES: The effects of industry payments to physicians on prescribing habits are not well understood. We aimed to determine the association between the receipt of industry payments and the prescribing of alpha-blockers and overactive bladder (OAB) medications.
METHODS: The Open Payments Program (OPP) database and Medicare Part D claims database for 2014 were linked. This provided industry payment information and prescription information for individual physicians in the US. We identified all physicians who prescribed any alpha-blocker or OAB drug. We also identified actively promoted drug (based on payments) within each group. Silodosin was the only actively promoted alpha-blocker. Fesoterodine, solifenacin, and mirabegron were the actively promoted OAB drugs. For each promoted drug, we calculated the proportion of physicians who 00 preferred 00 the promoted drug, i.e. prescribed the promoted drug more often than all other drugs in that class combined. Regression analysis was performed to quantify the effect of industry payment on 00 preferred 00 prescribing. Analysis was conducted for any payment, greater than the median payment, and high payment (>$100). Prescribing physicians were categorized as urologists or non-urologists.
RESULTS: In 2014, among the 108,680 physicians who prescribed an alpha blocker or an overactive bladder medication through Medicare Part D, 66,726 received at least one industry payment by the manufacturer of that drug. For each promoted drug, physicians who received any payment from its manufacturer prescribed that drug more often, relative to all drugs in its class. Receipt of payment from the promoting company was associated with significantly increased odds of preferentially prescribing that drug (Table 1) . This effect was significant when considering all physicians and non-urologists. However, when considering urologists alone, no significant effect was noted. Sensitivity analyses conducted using median payment and high payment thresholds confirmed these findings.
CONCLUSIONS: Receipt of industry payment is associated with increased prescribing of promoted urologic drugs. This effect varies according to specialty, possibly reflecting the strength of established prescribing patterns or close familiarity with these drugs for urologists as compared to other physicians. 
INTRODUCTION AND OBJECTIVES:
In the United States, the most common presentation for penile cancer (PC) is a distal, organ confined squamous cell cancer. Traditional treatment of PC in the form of total penectomy (TP) carries devastating functional and psychological outcomes. There is evidence that organ sparing surgery (OSS) has a higher rate of recurrence though that may not impact survival. We utilize the national cancer database to asses for a difference in survival among the different surgical options commonly used to treat T1/T2 penile cancer.
METHODS: Patients underwent OSS, partial penectomy (PP) and TP were identified. Demographic data including differences among the 3 groups were assessed using Chi-square test. Survival estimates were assessed using Kaplan-Meier estimate.
RESULTS: Between 2004 and 2014, 1,539 patients underwent surgery for T1/T2 penile cancer. There were 477 patients in the OSS group, 802 in the PP group and 202 in the TP group. Mean follow up in months was 44.6, 41.6 and 38.4 in the OSS, PP and TP groups respectively (p¼0.002). There was no difference in age or racial distribution among the 3 groups (p¼0.75 and 0.54 respectively). Overall, the three groups were more likely to receive treatment in an academic center, Medicare was the prevailing insurance type and most patients reside in Urban areas (p¼<0.001, <0.001 and 0.04 respectively). The incidence of T1/T2 in the OSS, PP and TP groups were 85.9/14.1, 39.8/ 50.2 and 37.7/62.3 respectively (p¼ <0.001). The 1,5 and 10 years survival rates for the 3 groups is illustrated in Table 1 . Predictors of poor survival were older age, black race and T2 disease. The type of surgery offered was not predictor of poor survival.
CONCLUSIONS: In the early stage penile cancer, which is the most common presenting stage in the United States, the degree of aggressiveness of initial surgical treatment did not alter the long term patient survival. Consideration for penile organ sparing surgery, which has better functional and psychological outcomes, should always be discussed with the patient. CONCLUSIONS: Our study illustrates that fewer patients are undergoing RPLND, which may be due to increased surveillance. RPLND is more commonly practiced at higher volume and academic centers. Education and race do not predict choice of treatment, whereas distance, income and insurance type do predict increased likelihood for receiving treatment overall.
Source of Funding: None

MP69-11 PATTERNS OF SURVEILLANCE INTENSITY IN KIDNEY CANCER
Suzanne Merrill*, Eric Schaefer, Chris Hollenbeak, Hershey, PA INTRODUCTION AND OBJECTIVES: Multiple surveillance guidelines exist for kidney cancer following surgical intervention. Although these recommendations lack conformity, the majority do use stage as well as surgery type to stratify surveillance intensity. Due to guideline heterogeneity, it remains unclear what factors influence surveillance intensity in current practice. Our objective was to assess the patterns of surveillance intensity in kidney cancer after primary surgical intervention among patients 66 years.
METHODS: Using SEER-Medicare, we identified patients diagnosed with non-metastatic kidney cancer who had undergone primary surgical intervention (n ¼ 2433) from 2007 to 2011. Surveillance intensity was measured as the number of unique inpatient and outpatient claims made for kidney cancer (ICD-9 diagnosis code 189.0) starting 60 days after primary intervention. Using multivariable linear regression, we assessed the relationships between patient related factors and surveillance intensity (log-transformed) . Parameters from the model were reported using risk ratios (RRs).
RESULTS: Patients diagnosed in later years experienced more surveillance with an estimated 10% greater number of visits/12months occurring with each subsequent calendar year (RR 1.10 for every 1-year increase, 95% CI 1.07-1.13, p<0.001). As compared to pT1 stage, patients with pT2-4 disease experienced 108% more surveillance visits/12 months (RR 2.08, 95%CI 1.90-2.27, p<0.001). Both older age and living in a metro/urban area, as compared to a big metropolitan location, were associated with significantly fewer follow-up visits (10-year increase in age: RR 0.89, 95%CI 0.83-0.95, p<0.001; metro/urban: RR 0.86, 95%CI 0.79-0.93, p<0.001). Surgery type (radical, partial or ablation), gender, race and Charlson comorbidity score were not significantly associated with surveillance.
CONCLUSIONS: Similar to guidelines, surveillance intensity in current practice was found to correlate with disease stage. However, surgery type played less of a role. Other factors such as year of diagnosis, location and younger patient age were associated with more surveillance administered. Further analysis is warranted to understand the reasons for this variation in current surveillance practice and its impact on oncologic care.
Source of Funding: None
MP69-12 UNDERUTILIZATION OF PALLIATIVE SERVICES IN ADVANCED GENITOURINARY MALIGNANCIES
Adrien Bernstein*, Ron Golan, Brian Dinerman, Jonathan Fainberg, Bashir Al Hussein Al Awamlh, Jim C. Hu, NEW YORK, NY INTRODUCTION AND OBJECTIVES: Comprehensive cancer care aims to reduce disease mortality while simultaneously maximizing patient quality of life. Palliative care addresses the morbidity of cancer and cancer treatments and should be offered in conjunction with traditional therapy. Recent randomized trials demonstrate that early referral to palliative care for advanced malignancy is associated with not only improved quality of life, but survival as well. Despite these findings, their services may remain underutilized. The aim of this study was to assess patterns of care in the use of palliative care services for advanced genitourinary malignancies.
METHODS: Data from the National Cancer Database was queried for Stage III and IV genitourinary malignancies (prostate, renal, bladder, penile, and testicular). Patient and facility characteristics were compared in those who received palliative care treatments versus those who did not. Comorbidities were stratified by Charlson-Deyo score. Logistic regression models were used to identify factors associated with palliative care.
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